References
- Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010; 62:600-10.10.1002/acr.20140
- Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res. 2000; 13: 42-50.10.1002/1529-0131(200002)13:1<;42::AID-ART7>3.0.CO;2-R11094925
- Couto CI, Natour J, Carvalho AB. Fibromyalgia: its prevalence and impact on the quality of life on a hemodialyzed population. Hemodial Int. 2008; 12: 66-72.1827184410.1111/j.1542-4758.2008.00243.x
- Assumpção A, Pagano T, Matsutani LA, Ferreira EAG. Pereira CAB, Marques AP. Quality of life and discriminating power of two questionnaires in fibromyalgia patients: fibromyalgia impact questionnaire and medical outcomes study 36-item short-form health survey. Rev Bras Fisioter. 2010; 14: 284-9.10.1590/S1413-3555201000500001520949228
- Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2007; 62:115-26.1803933010.1111/j.1742-1241.2007.01638.x
- Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheum. 2005; 32:5-21.
- Recla JM. New and emerging therapeutic agents for the treatment of fibromyalgia: an update. J Pain Res. 2010; 3:89-103.21197313
- Arnold LM. Biology and therapy of fibromyalgia: New therapies in fibromyalgia. Arthritis Res Ther. 2006; 8:212.1676204410.1186/ar1971
- Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010; 11:505-21.10.1016/j.jpain.2010.01.00220418173
- Bonnet F. [Mechanism of the analgesic effect of alpha 2 adrenergic agonists]. Cah Anesthesiol. 1994; 42:723-5. (in French)
- Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000; 355: 911-8.10.1016/S0140-6736(99)11381-310752718
- de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995; 10:19-23.10.1097/00004850-199512004-000048930006
- Wolfe F, Smythe HA, Yanus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter Criteria Committee. Arthritis Rheum. 1990; 33:160-72.10.1002/art.17803302032306288
- Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimeters? Pain. 1997; 72:95-7.10.1016/S0304-3959(97)00005-5
- Leurmarnkul W and Meetam P. Properties testing of the retranslated SF-36 (Thai version). Thai J Pharm Sci. 2005; 29:69-88.
- Jones GT, Atzeni F, Beasley M, Flüβ E, Sarzi-Puttini P. Macfarlane GJ. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheum. 2015; 2: 568-75.
- Verbunt JA, Pernot DHFM, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual life outcomes. 2008; 6:1-8.
- Birtane M, Uzunca K, Ta°tekin N, Tuna H. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol. 2007; 26:679-84.10.1007/s10067-006-0359-216897118
- Unruh A. Gender variations in clinical pain experience. Pain. 1996; 65:123-67.882650310.1016/0304-3959(95)00214-6
- Berkley K. Sex differences in pain. Behav Brain Sci. 1997; 20:371-80.10097000
- Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tölle TR, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin. 2006; 22: 257-64.1646659710.1185/030079906X80486
- Yodchai K, Dunning T, Savage S, Hutchinson AM, Oumtanee A. How do Thai patients receiving haemodialysis cope with pain? J Ren Care. 2014; 40: 205-15.10.1111/jorc.12073
- Martin MY, Bradley LA, Alexander RW, Alarcon GS, Triana-Alexander M, Aaron LA, et al. Coping strategies predict disability in patients with primary fibromyalgia. Pain. 1996; 68:45-53.925199710.1016/S0304-3959(96)03179-X
- Nicassio PM, Schoenfeld-Smith K, Radojevic V, Schuman C. Pain coping mechanisms in fibromyalgia: relationship to pain and functional outcome. J Rheumatol. 1995; 22:1552-8.7473482
- Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symp Man. 2002; 23: 442-7.10.1016/S0885-3924(02)00381-0